Zevra Therapeutics, Inc.
ZVRA
$12.28
-$0.40-3.12%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 9.51% | 6.14% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 9.51% | 6.14% | |||
| Cost of Revenue | -19.61% | 24.80% | |||
| Gross Profit | 11.11% | 5.27% | |||
| SG&A Expenses | -20.32% | 1.63% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -16.44% | 10.39% | |||
| Operating Income | 89.96% | -5.19% | |||
| Income Before Tax | -71.44% | 253.73% | |||
| Income Tax Expenses | -41.54% | 1,280.04% | |||
| Earnings from Continuing Operations | -76.90% | 211.47% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -76.90% | 211.47% | |||
| EBIT | 89.96% | -5.19% | |||
| EBITDA | 86.32% | -4.93% | |||
| EPS Basic | -77.18% | 196.38% | |||
| Normalized Basic EPS | 186.58% | -65.93% | |||
| EPS Diluted | -76.67% | 208.01% | |||
| Normalized Diluted EPS | 184.67% | -65.58% | |||
| Average Basic Shares Outstanding | 1.28% | 3.56% | |||
| Average Diluted Shares Outstanding | 1.84% | 2.60% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||